Aneil Batra

Aneil Batra is a transformational purpose-driven global healthcare executive with 30 years of experience building and scaling businesses, driving sustainable blockbuster growth, transforming pipelines, and building diverse team cultures of accountability and high performance. He has managed and propelled multibillion dollar blockbuster brands and is a trusted advisor to C-Suite leaders and Board of Directors.

At Pfizer Inc., Aneil reported to the Chief Business and Innovation Officer as the Obesity and IM Commercial Strategy & Innovation Lead. He led the development of the obesity and internal medicine category strategy leading to the acquisition of Metsera ($10B) and an oral GLP-1 from YaoPharma ($150M upfront). He set the clinical and commercial strategy for MET097 and MET097/MET233 fixed-dose combination.

At Novo Nordisk Inc., Aneil was a member of the Novo Nordisk US Management Board and the Global Obesity Management Board, serving as the top senior US executive accountable for the obesity business. During his tenure as Vice President, US Head of Obesity, Aneil built and scaled the obesity business from a ~$70M single-product startup to a ~$5B high-growth multi-product business, achieving 69% YOY volume increase and 50% YOY sales boost.